Showing results (1-10 of 200) with videos related to
Sort By:
Pageof 20
Molecular Cancer Research : MCR|October 30, 2014
Sensitizing B- and T- cell Lymphoma Cells to Paclitaxel/Abraxane-Induced Death by AS101 via Inhibition of the VLA-4-IL10-Survivin AxisHila Danoch, Yona Kalechman, Michael Albeck, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|June 19, 2007
The synthetic tellurium compound, AS101, is a novel inhibitor of IL-1beta converting enzymeMiri Brodsky, Sigal Yosef, Rushkin Galit, et al.Seminars in Cancer Biology|December 29, 2011
Immunomodulating tellurium compounds as anti-cancer agentsBenjamin SredniCancer Research|April 5, 2014
Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive stateAdi Layani-Bazar, Itai Skornick, Alain Berrebi, et al.Autoimmunity Reviews|August 26, 2014
The effect of the novel tellurium compound AS101 on autoimmune diseasesGilad Halpert, Benjamin SredniTransactions of the American Clinical and Climatological Association|July 23, 2013
Covert operations: cancer's many subversive tactics in overcoming host defensesDan L LongoBMC Hematology|February 7, 2014
An interview with Dan L. Longo, Section Editor of the Malignant hematological diseases sectionDan L LongoThe Journal of Antimicrobial Chemotherapy|May 26, 2012
Bactericidal activity of the organo-tellurium compound AS101 against Enterobacter cloacaeMiriam Daniel-Hoffmann, Benjamin Sredni, Yeshayahu NitzanPerspectives in Biology and Medicine|September 12, 2022
Darwinian Repurposing of Molecular Motifs in an Evolving Redox Environment and Its Biomedical ImplicationsJoseph Loscalzo, Dan L LongoSeminars in Cancer Biology|January 20, 2012
Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defensesArya Biragyn, Dan L LongoPageof 20